Akademik Veri Yönetim Sistemi
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2026 (SCI-Expanded, Scopus)
Recently R2-ISS (Revised International Staging System) and MASS (Mayo Additive Staging System) have been proposed for better staging and risk classification in newly diagnosed Multiple Myeloma (NDMM) patients. However, there is not enough data comparing these two staging systems. Two hundred twenty NDMM patients were included in our analysis. Survival analysis was conducted for R2-ISS and MASS. Median Overall Survival (OS) of the patients with R2-ISS low, low intermediate, high-intermediate and high groups were 85.5, 52, 45, and 13 months respectively (p = 0.012). The median OS of the patients according to MASS I, II, and III were 66, 62, and 24 months respectively (p = 0.001). We have also made a spearmen correlation analysis between MASS and R2-ISS. We have also found a strong positive correlation between MASS and R2-ISS (Spearmen Correlation Coefficient 0.781 p value = 0.001). Both R2-ISS and MASS are effective and valuable for staging NDMM. R2-ISS and MASS can distinguish patients and are practical enough to be utilized in routine evaluations.